18F-FDG PET improves diagnosis in patients with focal-onset dementias

Abstract

Alzheimer disease is the cause of up to one-third of cases of primary progressive aphasia or corticobasal syndrome. The primary objective of this study was to determine the accuracy of 18F-FDG PET metabolic imaging for the detection of Alzheimer disease in patients with primary progressive aphasia or corticobasal syndrome. Methods: A cohort of patients (n = 94), including those with an expert clinical diagnosis of logopenic (n = 19), nonfluent (n = 16), or semantic (n = 13) variants of primary progressive aphasia, corticobasal syndrome (n = 14), or Alzheimer disease (n = 24), underwent 18F-FDG metabolic and 11C-labeled Pittsburgh compound B (11C-PiB) amyloid PET brain imaging. 18F-FDG PET sc..